Gretchen G Kimmick1, Fabian Camacho2, Heath B Mackley2, Teresa Kern2, Nengliang Yao2, Stephen A Matthews2, Steven Fleming2, Joseph Lipscomb2, Jason Liao2, Wenke Hwang2, Roger T Anderson2. 1. Duke University Medical Center, Durham, NC; Penn State College of Medicine, State College, PA; Virginia Commonwealth University School of Medicine, Richmond, VA; University of Kentucky College of Public Health, Lexington, KY; and Emory University, Atlanta, GA gretchen.kimmick@duke.edu. 2. Duke University Medical Center, Durham, NC; Penn State College of Medicine, State College, PA; Virginia Commonwealth University School of Medicine, Richmond, VA; University of Kentucky College of Public Health, Lexington, KY; and Emory University, Atlanta, GA.
Abstract
PURPOSE: We describe individual, area, and provider characteristics associated with care patterns for early-stage breast cancer in Appalachian counties of Kentucky, North Carolina, Ohio, and Pennsylvania. METHODS: Cases of stages I to III breast cancer from 2006 to 2008 were linked to Medicare claims occurring within 1 year of diagnosis. Rates of guideline-concordant endocrine therapy (n = 1,429), chemotherapy (n = 1,480), and radiation therapy (RT) after breast-conserving surgery were studied; RT was studied in women age ≥ 70 years with stage I estrogen receptor (ER) -positive/progesterone receptor (PR) -positive cancer, for whom RT was optional (n = 1,108), and in all others, for whom RT was guideline concordant (n = 1,422). Univariable and multivariable analyses were performed. Independent variables included age, race, county-level economic status, state, surgeon graduation year and volume, comorbidity, diagnosis year, Medicaid/Medicare dual status, histology, tumor size, tumor sequence, positive lymph nodes, ER/PR status, stage, trastuzumab use, and surgery type. RESULTS: Population mean age was 74 years; 97% were white. For endocrine therapy, chemotherapy, and RT, guideline concordance was 76%, 48%, and 83%, respectively. Where it was optional, 77% received RT. Guideline-concordant endocrine therapy was lower in North Carolina versus Pennsylvania (odds ratio [OR], 0.60; 95% CI, 0.41 to 0.88) and higher if surgeon graduated between 1984 and 1988 versus ≥ 1989 (OR, 1.58; 95% CI, 1.06 to 2.34). Guideline-concordant chemotherapy varied significantly by state, county-level economic status, and surgeon volume. In guideline-concordant RT, lower surgeon volume (v highest) predicted RT use (OR, 1.63; 95% CI, 1.61 to 2.36). In optional RT, North Carolina residence (v Pennsylvania; OR, 0.29; 95% CI, 0.17 to 0.48) and counties with higher economic status (OR, 0.61; 95% CI, 0.40 to 0.94) predicated RT omission. CONCLUSION: Notable variation in care by geographic and surgical provider characteristics provides targets for further research in underserved areas.
PURPOSE: We describe individual, area, and provider characteristics associated with care patterns for early-stage breast cancer in Appalachian counties of Kentucky, North Carolina, Ohio, and Pennsylvania. METHODS: Cases of stages I to III breast cancer from 2006 to 2008 were linked to Medicare claims occurring within 1 year of diagnosis. Rates of guideline-concordant endocrine therapy (n = 1,429), chemotherapy (n = 1,480), and radiation therapy (RT) after breast-conserving surgery were studied; RT was studied in women age ≥ 70 years with stage I estrogen receptor (ER) -positive/progesterone receptor (PR) -positive cancer, for whom RT was optional (n = 1,108), and in all others, for whom RT was guideline concordant (n = 1,422). Univariable and multivariable analyses were performed. Independent variables included age, race, county-level economic status, state, surgeon graduation year and volume, comorbidity, diagnosis year, Medicaid/Medicare dual status, histology, tumor size, tumor sequence, positive lymph nodes, ER/PR status, stage, trastuzumab use, and surgery type. RESULTS: Population mean age was 74 years; 97% were white. For endocrine therapy, chemotherapy, and RT, guideline concordance was 76%, 48%, and 83%, respectively. Where it was optional, 77% received RT. Guideline-concordant endocrine therapy was lower in North Carolina versus Pennsylvania (odds ratio [OR], 0.60; 95% CI, 0.41 to 0.88) and higher if surgeon graduated between 1984 and 1988 versus ≥ 1989 (OR, 1.58; 95% CI, 1.06 to 2.34). Guideline-concordant chemotherapy varied significantly by state, county-level economic status, and surgeon volume. In guideline-concordant RT, lower surgeon volume (v highest) predicted RT use (OR, 1.63; 95% CI, 1.61 to 2.36). In optional RT, North Carolina residence (v Pennsylvania; OR, 0.29; 95% CI, 0.17 to 0.48) and counties with higher economic status (OR, 0.61; 95% CI, 0.40 to 0.94) predicated RT omission. CONCLUSION: Notable variation in care by geographic and surgical provider characteristics provides targets for further research in underserved areas.
Authors: Steven J Katz; Timothy P Hofer; Sarah Hawley; Paula M Lantz; Nancy K Janz; Kendra Schwartz; Lihua Liu; Dennis Deapen; Monica Morrow Journal: J Clin Oncol Date: 2007-01-20 Impact factor: 44.544
Authors: Jennifer J Griggs; Eva Culakova; Melony E S Sorbero; Marek S Poniewierski; Debra A Wolff; Jeffrey Crawford; David C Dale; Gary H Lyman Journal: J Clin Oncol Date: 2007-06-20 Impact factor: 44.544
Authors: R W Blamey; T Bates; U Chetty; S W Duffy; I O Ellis; D George; E Mallon; M J Mitchell; I Monypenny; D A L Morgan; R D Macmillan; J Patnick; S E Pinder Journal: Eur J Cancer Date: 2013-03-21 Impact factor: 9.162
Authors: Roberto Gennari; Giuseppe Curigliano; Nicole Rotmensz; Chris Robertson; Marco Colleoni; Stefano Zurrida; Franco Nolè; Filippo de Braud; Laura Orlando; Maria Cristina Leonardi; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Giuseppe Renne; Saverio Cinieri; Riccardo A Audisio; Alberto Luini; Roberto Orecchia; Giuseppe Viale; Aron Goldhirsch Journal: Cancer Date: 2004-09-15 Impact factor: 6.860
Authors: Andrea N Burnett-Hartman; Natalia Udaltsova; Lawrence H Kushi; Christine Neslund-Dudas; Alanna Kulchak Rahm; Pamala A Pawloski; Douglas A Corley; Sarah Knerr; Heather Spencer Feigelson; Jessica Ezzell Hunter; David C Tabano; Mara M Epstein; Stacey A Honda; Monica Ter-Minassian; Julie A Lynch; Christine Y Lu Journal: JCO Clin Cancer Inform Date: 2019-09
Authors: Xi Tan; Fabian Camacho; Vincent D Marshall; Joseph Donohoe; Roger T Anderson; Rajesh Balkrishnan Journal: Res Social Adm Pharm Date: 2016-08-25
Authors: Leticia M Nogueira; Helmneh M Sineshaw; Ahmedin Jemal; Craig E Pollack; Jason A Efstathiou; K Robin Yabroff Journal: JAMA Netw Open Date: 2022-04-01